Earendil Labs
United States · Biotech · Healthtech · AI
Earendil Labs develops protein therapeutics using AI models coupled with experimental antibody discovery and validation.
An experimental loop for antibody design
Earendil Labs combines computational protein design with laboratory testing to develop therapeutic antibodies. Its platform generates candidate sequences, predicts molecular properties and tests the resulting proteins experimentally, using those results to refine subsequent designs. The work spans antibody structure, binding, stability and other properties needed to advance a drug candidate.
Internal medicines and pharmaceutical partnerships
The company applies the platform to its own immunology and oncology pipeline and to collaborations with pharmaceutical companies. Its programs include antibodies, bispecific and multispecific molecules. Earendil works with Sanofi on autoimmune and inflammatory disease programs, combining licensing relationships with broader discovery collaborations.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Financing rounds disclosure | Undisclosed | Biotech Development Fund — ParticipantDimension — ParticipantDST Global — ParticipantINCE Capital — ParticipantLuminous Ventures — ParticipantMiracle Capital — ParticipantSanofi — Participant |